Retina

Nitish Mehta, MD discusses the latest trends in Artificial Intelligence and Machine Learning technology in retinal imaging and its uses for ophthalmologists.

Learning more about the early AD stages, when brain damage is limited, should allow early and more efficacious treatment, and improvements in imaging may be able to pick up changes earlier.

According to researchers, diabetes mellitus is caused by higher levels of blood glucose due to the lack of production of insulin by the body, resistance to insulin, or both.

This subtype of artificial intelligence technology may have long-range implications for clinical trials.

According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.

Researchers conducted a retrospective analysis of longitudinal, clinical data from patients with high myopic MNV treated with intravitreal bevacizumab.

According to researchers, patients with chronic CSC treated with 1 fovea-involving, half-dose PTD application had a significant improvement in structure and function at the final follow-up and foveal atrophy did not develop in any patients.

Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 300 to 600 patients in the United States per year.

Despite its promise, RGC replacement represents a more formidable challenge.

Artificial intelligence (AI) with ultra-widefield fundus autofluorescence images may be helpful to objectively estimate progression of retinitis pigmentosa (RP) and visual function.

Yusuke Oshima, MD, PhD, in a presentation at the 38th Asia-Pacific Academy of Ophthalmology Congress, Kuala Lumpur, Malaysia, discussed the advantages of using a beveled-tip ultra-speed probe for complete vitreous shaving during retinal detachment vitrectomies.

Analysis of data from the pooled Tenaya and Lucerne studies showed the faricimab achieved greater anatomic improvements compared to aflibercept during the matched-dosing period.

Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.

The considerations for biosimilars in clinical practice are interesting and remain to be determined, according to George A. Williams, MD.

Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss new and upcoming clinical trials, investigational therapies, and diagnostic tools for the treatment of diabetic retinopathy and diabetic macular edema (DR/DME).

Diabetic retinal disease experts discuss different approaches that can reduce the treatment burden while maintaining good visual outcomes during diabetic retinopathy and diabetic macular edema (DR/DME) therapy.

Rishi Singh, MD, provides an overview of the various treatment options available for diabetic retinopathy and diabetic macular edema (DR/DME).

The company announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

Three of Frontera’s gene therapy product candidates have entered clinical trials since the beginning of the year.

According to a news release, Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024.

The collaboration may provide insights to help improve the treatment paradigm for retinal disorders.

The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.

Sharing data between ophthalmologists, optometrists can lead to earlier diagnosis

The findings from a National Institutes of Health-supported clinical trial may help guide the management of diabetic eye disease.